Could a simple nutritional drink boost recovery in pancreatic cancer patients?
NCT ID NCT06852014
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a special nutritional formula (Peptamen 1.6) helps malnourished pancreatic cancer patients recover better after a major surgery called pancreaticoduodenectomy. Twenty adults who are malnourished or at risk will receive two different nutritional drinks in a random order, and researchers will measure digestion, nutrient absorption, inflammation, and gut health. The goal is to find out which formula works best to improve recovery and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Peptamen 1.6 (a hydrolysed whey protein-based enteral formula)
- What this could lead to
- If it works, this could point toward better nutritional support to improve recovery after pancreatic cancer surgery.
- What could go wrong
- This is a very small early-stage trial with only 20 people, so results may not apply widely. It tests nutritional supplements, not a cure, and success is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ambulatory patients who are malnourished or at risk of malnutrition, with a confirmed diagnosis of neoplasms of the periampullary region, pancreas, and duodenum, or pancreatic cancer, and who have undergone cephalic pancreaticoduodenectomy (CPD). * No prior neoadjuvant treatment (preoperative chemotherapy or radiotherapy): Patients must not have received neoadjuvant therapy as these treatments can affect metabolism, nutritional status, and gut microbiota, potentially interfering with the objectives of the study's nutritional intervention. Exclusion Criteria: * Refusal to sign informed consent: Informed consent is a mandatory requirement for study participation. Any patient unwilling to participate voluntarily will be excluded. * Patients who underwent surgery more than three months ago will be excluded, as the nutritional intervention must begin in the immediate postoperative period to adequately evaluate its impact on nutritional and metabolic status. * Presence of severe cardiac disease, nephropathy, or other severe comorbidities: Conditions such as severe cardiac disease, renal failure, or comorbidities that could induce malnutrition or impair the patient's ability to tolerate nutritional treatment will be exclusion criteria. These conditions may interfere with assessing the effects of nutritional supplementation in the context of pancreatic cancer treatment. * Diarrhoea associated with antibiotics, laxatives, or osmotically active agents: Diarrhoea caused by medications may alter nutrient absorption and affect tolerance to the nutritional supplement, potentially skewing results attributable solely to the nutritional intervention. * Treatment with other nutritional support: Patients receiving other oral nutritional supplement, enteral or parenteral nutrition will be excluded, as interactions with the studied formula could confound the efficacy results of the study's nutritional intervention. * Pregnancy or possibility of becoming pregnant. * Type 1 or Type 2 diabetes with HbA1c \>8%. * Galactosaemia, fructosaemia, or allergies to components of the nutritional supplement.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cephalic duodenopancreatectomy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Regional Universitario de Málaga
RECRUITINGMálaga, Málaga, 29009, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- New scan could spot hidden cancers faster and more accurately
- Can a health coach ease the burden of pancreatic cancer?
- New study aims to catch pancreatic cancer early in High-Risk individuals
- Can your mood impact pancreatic cancer survival?
- Simple blood test could spot hidden pancreatic cancer in new diabetes patients